Diagnostics of the Epstein-Barr Virus Before and After Lung Transplantation in a Patient With Developing Posttransplant Lymphoproliferative Disease: A Case Report.

ABSTRACT

The most important risk factor for the development of posttransplant lymphoproliferative disorders (PTLD) is Epstein-Barr virus (EBV) infection after transplant. It increases in seronegative EBV recipients from 23% to 50%. The aim of the study was to assess the serologic status of EBV infections (before lung transplant) and the expression of the virus itself after lung transplant in a 25-year-old patient with cystic fibrosis. In a 25-year-old patient with cystic fibrosis, immediately before lung transplant, all diagnostically significant antibodies related to EBV infection were determined in blood serum using enzyme-linked immunosorbent assay methods, using tests by Euroimmun and PerkinElmer Company. Additionally, the organ donor's serologic profile was assessed with the same tests. After lung transplant, the risk of EBV infection was monitored in whole blood and virus expression was determined by reverse transcriptase-polymerase chain reaction with Biomerieux Argene tests. Before lung transplant, the patient was shown to have no antibodies against EBV in both IgM and IgG classes. The constellation of organ donor antibodies clearly indicated a past infection. The presence of EBV virus copies in whole blood was demonstrated in the patient 9 months after transplant. Constant monitoring of the patient and modification of the treatment did not, unfortunately, protect him from the development of PTLD. The obtained results clearly confirm the purposefulness of both serologic and molecular determinations in lung recipients related to EBV. The likelihood of developing PTLD increases both in people who have not had EBV infection and patients with reactivation of the infection.